|
1. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec 2008; 291(6): 684–92. 2. Jamali R, JamaliA.Non-alcoholic fatty liver disease. Feyz 2010; 14: 169–79. [in Persian] 3. Trauner M, Arrease M, Wangner M. Fatty liver and lipotoxicity. Biochem Biophys Acta 2010; 1801(3): 299–310. 4. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham Heart Study. Hepatol 2010; 51(6): 1979–87. 5. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatol 2019; 69(6): 2672-82. 6. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease.BMC Med 2017; 15(1): 45. 7. Bouneva I, Kirby D. Management of nonalcoholic fatty liver disease: weight control. Clin Liver Dis 2004; 8(3): 693–713. 8. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. ObesSurg 2002; 12(1): 49-51. 9. Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol2011; 46(6): 769–78. 10. Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, Shirazinia M, Ghodsi H, Rouhbakhsh Zahmatkesh MR. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. SAGE Open Med 2018; 24(6): 2050312117745223. 11. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114(2): 147–52. 12. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatol2010; 51(2): 679–89. 13. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009; 9(5): 407–16. 14. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13(9): 1016–23. 15. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016: 65(8): 1038–48. 16. García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008; 90(3): 460–6. 17. Yuan H, Shyy JY, Martins-Green M. Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. J Hepatol2009; 51(3): 535–547. 18. Jang ES, Jeong SH, Hwang SH, Kim HY, Ahn SY, Lee J, et al. Effects of coffee, smoking, and alcohol on liver function tests: a comprehensive cross-sectional study. BMC Gastroenterol 2012;18(12):145. 19. Murphy TL, McIvor C, Yap A, Cooksley WG, Halliday JW, Powell LW. The effect of smoking on caffeine elimination: implications for its use as a semiquantitative test of liver function. Clin Exp Pharmacol Physiol 1988;15(1):9-13. 20. Wannamethee SG, Shaper Sh. Cigarette smoking and serum liver enzymes: the role of alcohol and inflammation. Ann Clin Biochem 2010; 47(Pt 4): 321-6. 21. Liu Y, Dai M, Bi Y, Xu M, Xu Y, Li M, et al. Active Smoking, Passive Smoking, and Risk of Nonalcoholic Fatty Liver Disease (NAFLD): A Population-Based Study in China. J Epidemiol 2013; 23(2): 115-21. 22. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterol 2009; 137(3): 865-72. 23. Yuen ST, Gogo AR, Luk IS, Cho CH, Ho JC,Loh TT. The effect of nicotine and its interaction with carbon tetrachloride in the rat liver. PharmacolToxicol 1995; 77(3): 225–30. 24. Chakraborty A. and Selvaraj S. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamine induced hepa-tocarcinogenesis in Sprague-dawley rats. Neo-Plasma 2000; 47(2): 81–9. 25. Pannuru P, Vaddi D, Nallanchakravarthula V. Influence of Chronic Cigarette Smoking on Se-rum Biochemical Profile in Male Human Volunteers. JHealth Sci 2009; 55(2): 265–70. 26. Friedman TC, Sinha-Hikim I, Parveen M, Najjar SM, Liu Y, Mangubat M, et al. Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. Endocrinol 2012; 153(12): 5809-20. 27. Avti PK, Kumar S, Pathak CM, Vaipehei K, Khanduja KL. Smokeless tobacco impairs the antioxidant defense in liver, lung and kidney of rats. ToxicolSci 2006; 89(2): 547–53. 28. El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol 2006; 12(38): 6098–101. 29. Battaler R. Time to ban smoking in patients with chronic liver diseases. Hepatol 2006; 44(6): 1394–6. 30. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42(2): 218–24. 31. Azzalini L, Ferrer E, Ramalho LN, Moreno M, Domínguez M, Colmenero J, et al. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatol 2010; 51(5): 1567–76. 32. Liu Y, Dai M, Bi Y, Xu M, Xu Y, Li M, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol 2013; 23(2): 115-21. 33. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett, WC, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. NEJM 2018; 379(16): 623-32. 34. Liu G, Hu Y, Zong G, Pan A, Manson JE, Rexrode KM, et al. Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study. Lancet Diab Endocrinol 2020; 8(2): 125-33.
|
.png){kind=logo}
